GlassScriptPhysician profile
Arian S Hilsendager
NPI 1922477710
$2,395.05
in general payments reported to CMS, 2019-2025
24 companies · $556 in 2025
The $556 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.30 · 2022: $375 · 2023: $693 · 2024: $733 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.92 |
| Education | $111.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.54 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $371.40 | 2022-2025 | |
| Astellas Pharma US INC | $348.38 | 2023-2025 | Veozah, Cresemba, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $251.28 | 2021-2025 | |
| Exeltis, USA INC. | $187.45 | 2022-2025 | Slynd |
| Medtronic, INC. | $137.18 | 2024 | Abre |
| Coopersurgical, INC. | $105.29 | 2022-2025 | Paragard T 380a, Paragard T 380a, Sos |
| Hologic Sales and Service, LLC | $67.27 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Merck Sharp & Dohme LLC | $61.55 | 2022-2025 | Gardasil 9, Gardasil |
| Organon LLC | $60.12 | 2023-2024 | Nexplanon |
| Exact Sciences Corporation | $49.43 | 2023-2025 | Cologuard Collection Kit |
| Millicent US INC | $43.22 | 2024-2025 | Femring, Intrarosa |
| Shield Therapeutics INC | $39.08 | 2023-2024 | Accrufer |
| Sage Therapeutics, LLC | $37.51 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $35.22 | 2024 | Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $34.99 | 2021-2022 | |
| Pfizer INC. | $33.35 | 2023-2024 | |
| Boston Scientific Corporation | $33.28 | 2025 | Rezum Generator |
| Bausch Health US, LLC | $22.25 | 2024 | Aplenzin |
| Sumitomo Pharma America, INC. | $20.81 | 2023 | Myfembree |
| Smith+Nephew, INC. | $19.86 | 2025 | Pico |
| Sanofi-Aventis U.S. LLC | $18.76 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.13 | 2023 | Quviviq |
| C. R. Bard, INC. & Subsidiaries | $13.70 | 2024 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arian Hilsendager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.